← Back to Screener
BIOMERICA INC (BMRA)
Price$2.20
Favorite Metrics
Price vs S&P 500 (26W)-30.72%
Price vs S&P 500 (4W)-7.22%
Market Capitalization$6.52M
All Metrics
Book Value / Share (Quarterly)$1.50
P/TBV (Annual)2.23x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-34.47%
Cash Flow / Share (Quarterly)$-1.01
Price vs S&P 500 (YTD)-18.91%
Gross Margin (TTM)5.61%
Net Profit Margin (TTM)-90.29%
EPS (TTM)$-1.64
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1.64
Revenue Growth (5Y)-4.51%
EPS (Annual)$-2.16
ROI (Annual)-121.14%
Gross Margin (Annual)9.38%
Net Profit Margin (5Y Avg)-93.05%
Cash / Share (Quarterly)$0.86
Revenue Growth QoQ (YoY)-26.04%
ROA (Last FY)-83.65%
Revenue Growth TTM (YoY)-20.05%
EBITD / Share (TTM)$-2.04
ROE (5Y Avg)-81.57%
Operating Margin (TTM)-118.10%
Cash Flow / Share (Annual)$-1.52
P/B Ratio1.47x
P/B Ratio (Quarterly)1.50x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.89x
Net Interest Coverage (TTM)83.00x
ROA (TTM)-61.43%
EV / EBITDA (TTM)16.57x
EPS Incl Extra (Annual)$-2.16
Current Ratio (Annual)2.80x
Quick Ratio (Quarterly)2.18x
3-Month Avg Trading Volume0.05M
52-Week Price Return-52.05%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.43
P/S Ratio (Annual)1.23x
Asset Turnover (Annual)0.89x
52-Week High$4.88
Operating Margin (5Y Avg)-95.54%
EPS Excl Extra (Annual)$-2.16
CapEx CAGR (5Y)-20.97%
Tangible BV CAGR (5Y)-22.69%
26-Week Price Return-26.74%
Quick Ratio (Annual)1.80x
13-Week Price Return-21.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.25x
Enterprise Value$3.978
Revenue / Share Growth (5Y)28.58%
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)5.90%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.49x
Pretax Margin (Annual)-93.62%
Cash / Share (Annual)$0.94
3-Month Return Std Dev54.15%
Gross Margin (5Y Avg)10.00%
Net Income / Employee (TTM)$-0
ROE (Last FY)-121.14%
Net Interest Coverage (Annual)55.67x
EPS Basic Excl Extra (Annual)$-2.16
P/FCF (TTM)1.80x
Receivables Turnover (TTM)3.92x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.64
Receivables Turnover (Annual)6.33x
ROI (TTM)-83.73%
P/S Ratio (TTM)1.46x
Pretax Margin (5Y Avg)-92.62%
Revenue / Share (Annual)$2.31
Tangible BV / Share (Annual)$1.52
Price vs S&P 500 (52W)-81.88%
Year-to-Date Return-16.27%
5-Day Price Return-4.09%
EPS Normalized (Annual)$-2.16
ROA (5Y Avg)-60.11%
Net Profit Margin (Annual)-93.64%
Month-to-Date Return-0.47%
Cash Flow / Share (TTM)$-0.41
EBITD / Share (Annual)$-2.20
Operating Margin (Annual)-96.72%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-81.57%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.64
P/TBV (Quarterly)1.58x
P/B Ratio (Annual)2.10x
Inventory Turnover (TTM)2.54x
Pretax Margin (TTM)-90.09%
Book Value / Share (Annual)$1.61
Price vs S&P 500 (13W)-21.96%
Beta0.26x
P/FCF (Annual)5.77x
Revenue / Share (TTM)$1.53
ROE (TTM)-83.73%
52-Week Low$1.87
Analyst Recommendations
Apr 2022
May 2022
Jun 2022
Jul 2022
4.29
4.29
4.29
4.29
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BMRABIOMERICA INC | 1.46x | -20.05% | 5.61% | — | $2.20 |
IDXXIdexx Laboratories Inc | 10.59x | 10.42% | 61.80% | 14.28% | $569.95 |
LNTHLantheus Holdings, Inc | 3.53x | 0.50% | 61.10% | 40.71% | $83.92 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 299.06x | -5.72% | 89.00% | — | $27.80 |
CLDXCelldex Therapeutics, Inc | 1718.98x | -77.98% | 17.65% | — | $33.86 |
NEOGNeogen Corp | 2.32x | -3.91% | 45.20% | — | $9.24 |
NTLAIntellia Therapeutics, Inc | 26.08x | 16.92% | — | — | $14.16 |
QDELQuidelOrtho Corporation Common Stock | 0.31x | -1.89% | 46.67% | — | $12.69 |
MYGNMyriad Genetics Inc | 0.58x | -1.56% | 69.93% | — | $5.00 |
ACHVAchieve Life Sciences, Inc. | 14.37x | -89.25% | — | — | $4.81 |
TKNOAlpha Teknova, Inc. Common Stock | 3.62x | 7.35% | 33.17% | — | $2.68 |
About
Biomerica develops and markets medical diagnostic products for early detection and monitoring of chronic diseases, with a focus on gastrointestinal conditions, food intolerances, and diabetes. The company generates the majority of its revenue from Asia while maintaining a global presence across Europe, North America, the Middle East, and South America.